• A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia

  NCT02553187

  Unknown statusInterventionalPhase 4Updated Feb 15, 2017
• Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT03986528

  Unknown statusInterventionalPhase 4Updated Feb 23, 2021
• Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

  NCT01640730

  TerminatedInterventionalPhase 2Updated Jan 16, 2014
• A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia

  NCT07243379

  RecruitingInterventionalPhase 4Updated Nov 21, 2025
• Real-World Clinical Study for Malignant Tumor-Induced Cachexia

  NCT07008248

  WithdrawnObservationalUpdated Aug 8, 2025
• Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

  NCT07185308

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 25, 2025

ClinicalTrials.gov ID

NCT03631459

Lead Sponsor

Zhejiang Kanglaite Pharmaceutical Co.LtdOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

100,000Estimated

Last Update Posted

Aug 21, 2018Actual

Start Date

Aug 20, 2018Estimated

Primary Completion Date

Mar 20, 2020Estimated

Completion Date

Jul 20, 2020Estimated

Official Title

Safety and Effectiveness of Kanglaite Injection/Capsules for Treatment of Cancer Cachexia: A Prospective, Multicenter Real World Study of a Large Cohort of Chinese Patients

Brief Summary

A prospective, multi-center real-world study of the effectiveness and safety of Kanglaita Injection/Capsule in Chinese patients with cancer cachexia

Detailed Description

This is a large national-based prospective, multi-center real-world observational study. Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited to evaluate the effectiveness and safety of Kanglaite.

• Cancer Cachexia

• Kanglaite Injection/Capsules

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Patients with pathological or cytological diagnosis of lung, liver, pancreatic or stomach cancer; Patients scheduled to receive Kanglaite injection for 7 or more days, followed by Kanglaite capsule for 14 or more days; Patients willing to participate in this study and provide written informed consent.

Exclusion Criteria:

None

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Zhejiang Kanglaite Pharmaceutical Co.LtdOTHER

Collaborators

NanJing PLA 81 HospitalOTHER

LinkDoc Technology (Beijing) Co. Ltd.INDUSTRY

qinsk@csco.org.cn+86-025-84453932